Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interleukin-15-activated cytokine-induced killer cells may sustain remission in leukemia patients after allogeneic stem cell transplantation: feasibility, safety and first insights on efficacy.
Rettinger E, Huenecke S, Bonig H, Merker M, Jarisch A, Soerensen J, Willasch A, Bug G, Schulz A, Klingebiel T, Bader P. Rettinger E, et al. Among authors: merker m. Haematologica. 2016 Apr;101(4):e153-6. doi: 10.3324/haematol.2015.138016. Epub 2016 Jan 14. Haematologica. 2016. PMID: 26768688 Free PMC article. No abstract available.
Immunomagnetic selection or irradiation eliminates alloreactive cells but also reduces anti-tumor potential of cytokine-induced killer cells: implications for unmanipulated cytokine-induced killer cell infusion.
Rettinger E, Kreyenberg H, Merker M, Kuçi S, Willasch A, Bug G, Ullrich E, Wels WS, Bonig H, Klingebiel T, Bader P. Rettinger E, et al. Among authors: merker m. Cytotherapy. 2014 Jun;16(6):835-44. doi: 10.1016/j.jcyt.2014.01.003. Epub 2014 Feb 28. Cytotherapy. 2014. PMID: 24582456
Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL: the Frankfurt experience.
Willasch AM, Salzmann-Manrique E, Krenn T, Duerken M, Faber J, Opper J, Kreyenberg H, Bager R, Huenecke S, Cappel C, Bremm M, Pfirrmann V, Merker M, Ullrich E, Bakhtiar S, Rettinger E, Jarisch A, Soerensen J, Klingebiel TE, Bader P. Willasch AM, et al. Among authors: merker m. Bone Marrow Transplant. 2017 Feb;52(2):201-208. doi: 10.1038/bmt.2016.224. Epub 2016 Sep 19. Bone Marrow Transplant. 2017. PMID: 27643863 Clinical Trial.
Pre-Emptive Immunotherapy for Clearance of Molecular Disease in Childhood Acute Lymphoblastic Leukemia after Transplantation.
Rettinger E, Merker M, Salzmann-Manrique E, Kreyenberg H, Krenn T, Dürken M, Faber J, Huenecke S, Cappel C, Bremm M, Willasch A, Bakhtiar S, Jarisch A, Soerensen J, Klingebiel T, Bader P. Rettinger E, et al. Among authors: merker m. Biol Blood Marrow Transplant. 2017 Jan;23(1):87-95. doi: 10.1016/j.bbmt.2016.10.006. Epub 2016 Oct 11. Biol Blood Marrow Transplant. 2017. PMID: 27742575 Free article.
Haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk soft tissue sarcomas: results of a single-center prospective trial.
Merker M, Meister MT, Rettinger E, Jarisch A, Soerensen J, Willasch A, Huenecke S, Cappel C, Bremm M, Salzmann-Manrique E, Krenn T, Rossig C, Kremens B, Koscielniak E, Klingebiel T, Bader P. Merker M, et al. Bone Marrow Transplant. 2018 Jul;53(7):891-894. doi: 10.1038/s41409-018-0088-6. Epub 2018 Jan 24. Bone Marrow Transplant. 2018. PMID: 29367709 No abstract available.
AlloHSCT in paediatric ALL and AML in complete remission: improvement over time impacted by accreditation?
Bakhtiar S, Salzmann-Manrique E, Hutter M, Krenn T, Duerken M, Faber J, Reinhard H, Kreyenberg H, Huenecke S, Cappel C, Bremm M, Pfirrmann V, Merker M, Barnbrock A, Schöning S, Willasch AM, Rettinger E, Soerensen J, Klingebiel TE, Jarisch A, Bader P. Bakhtiar S, et al. Among authors: merker m. Bone Marrow Transplant. 2019 May;54(5):737-745. doi: 10.1038/s41409-018-0341-z. Epub 2018 Sep 26. Bone Marrow Transplant. 2019. PMID: 30258130 Clinical Trial.
Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte Infusions.
Merker M, Salzmann-Manrique E, Katzki V, Huenecke S, Bremm M, Bakhtiar S, Willasch A, Jarisch A, Soerensen J, Schulz A, Meisel R, Bug G, Bonig H, Klingebiel T, Bader P, Rettinger E. Merker M, et al. Biol Blood Marrow Transplant. 2019 Jul;25(7):1281-1292. doi: 10.1016/j.bbmt.2019.03.004. Epub 2019 Mar 13. Biol Blood Marrow Transplant. 2019. PMID: 30878607 Free article. Clinical Trial.
Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells.
Bremm M, Pfeffermann LM, Cappel C, Katzki V, Erben S, Betz S, Quaiser A, Merker M, Bonig H, Schmidt M, Klingebiel T, Bader P, Huenecke S, Rettinger E. Bremm M, et al. Among authors: merker m. Front Immunol. 2019 May 31;10:1218. doi: 10.3389/fimmu.2019.01218. eCollection 2019. Front Immunol. 2019. PMID: 31214182 Free PMC article.
186 results